Loading...

TG Therapeutics

DB:NKB2
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
NKB2
DB
$666M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s Lymphoma (NHL), and Multiple Sclerosis (MS). The last earnings update was 47 days ago. More info.


Add to Portfolio Compare Print
  • TG Therapeutics has significant price volatility in the past 3 months.
NKB2 Share Price and Events
7 Day Returns
-0.2%
DB:NKB2
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
-37.9%
DB:NKB2
-7.9%
DE Biotechs
-7.2%
DE Market
NKB2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
TG Therapeutics (NKB2) -0.2% 16.7% 75.9% -37.9% -19.8% 67.3%
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • NKB2 underperformed the Biotechs industry which returned -7.9% over the past year.
  • NKB2 underperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
NKB2
Industry
5yr Volatility vs Market
Related Companies

NKB2 Value

 Is TG Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of TG Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for TG Therapeutics.

DB:NKB2 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:NKB2
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.46
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.456 (1 + (1- 21%) (0.01%))
1.306
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.31
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.306 * 5.96%)
8.01%

Discounted Cash Flow Calculation for DB:NKB2 using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for TG Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:NKB2 DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.01%)
2019 -137.00 Analyst x2 -126.84
2020 -125.50 Analyst x2 -107.58
2021 -119.00 Analyst x2 -94.44
2022 -28.00 Analyst x2 -20.57
2023 54.00 Analyst x2 36.74
2024 83.21 Est @ 54.09% 52.41
2025 114.77 Est @ 37.93% 66.93
2026 145.32 Est @ 26.62% 78.46
2027 172.50 Est @ 18.7% 86.22
2028 195.20 Est @ 13.16% 90.34
Present value of next 10 years cash flows $61.65
DB:NKB2 DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $195.20 × (1 + 0.23%) ÷ (8.01% – 0.23%)
$2,514.25
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,514.25 ÷ (1 + 8.01%)10
$1,163.57
DB:NKB2 Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $61.65 + $1,163.57
$1,225.22
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,225.22 / 81.87
$14.96
DB:NKB2 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:NKB2 represents 0.85565x of NasdaqCM:TGTX
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.85565x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 14.96 x 0.85565
€12.80
Value per share (EUR) From above. €12.80
Current discount Discount to share price of €6.97
= -1 x (€6.97 - €12.80) / €12.80
45.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price TG Therapeutics is available for.
Intrinsic value
46%
Share price is €6.97 vs Future cash flow value of €12.8
Current Discount Checks
For TG Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • TG Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • TG Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for TG Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are TG Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:NKB2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.30
NasdaqCM:TGTX Share Price ** NasdaqCM (2019-04-17) in USD $8.14
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of TG Therapeutics.

DB:NKB2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:TGTX Share Price ÷ EPS (both in USD)

= 8.14 ÷ -2.30

-3.54x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TG Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • TG Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does TG Therapeutics's expected growth come at a high price?
Raw Data
DB:NKB2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.54x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
32.9%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for TG Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on TG Therapeutics's assets?
Raw Data
DB:NKB2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.31
NasdaqCM:TGTX Share Price * NasdaqCM (2019-04-17) in USD $8.14
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:NKB2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:TGTX Share Price ÷ Book Value per Share (both in USD)

= 8.14 ÷ 0.31

26.34x

* Primary Listing of TG Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • TG Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess TG Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. TG Therapeutics has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

NKB2 Future Performance

 How is TG Therapeutics expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
32.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is TG Therapeutics expected to grow at an attractive rate?
  • TG Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • TG Therapeutics's earnings growth is expected to exceed the Germany market average.
  • TG Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:NKB2 Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:NKB2 Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 32.9%
DB:NKB2 Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 60.2%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:NKB2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:NKB2 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 384 56 51 3
2022-12-31 234 -4 -34 4
2021-12-31 64 -121 -145 5
2020-12-31 17 -123 -133 5
2019-12-31 0 -139 -140 5
DB:NKB2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -129 -173
2018-09-30 0 -117 -150
2018-06-30 0 -107 -148
2018-03-31 0 -100 -132
2017-12-31 0 -94 -118
2017-09-30 0 -89 -111
2017-06-30 0 -81 -105
2017-03-31 0 -67 -92
2016-12-31 0 -62 -78
2016-09-30 0 -57 -72
2016-06-30 0 -53 -61
2016-03-31 0 -52 -62

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • TG Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • TG Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:NKB2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from TG Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NKB2 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.44 0.52 0.40 3.00
2022-12-31 -0.31 -0.09 -0.40 4.00
2021-12-31 -1.44 -1.04 -1.59 4.00
2020-12-31 -1.35 -0.84 -1.71 6.00
2019-12-31 -1.63 -1.15 -1.91 6.00
DB:NKB2 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.30
2018-09-30 -2.08
2018-06-30 -2.14
2018-03-31 -1.99
2017-12-31 -1.91
2017-09-30 -1.93
2017-06-30 -1.95
2017-03-31 -1.84
2016-12-31 -1.60
2016-09-30 -1.48
2016-06-30 -1.26
2016-03-31 -1.31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if TG Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess TG Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
TG Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

NKB2 Past Performance

  How has TG Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare TG Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • TG Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare TG Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare TG Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
TG Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from TG Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:NKB2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.15 -173.48 15.16 159.39
2018-09-30 0.15 -150.48 18.33 133.11
2018-06-30 0.15 -148.07 21.83 126.86
2018-03-31 0.15 -132.28 17.91 114.87
2017-12-31 0.15 -118.48 16.33 102.53
2017-09-30 0.15 -111.29 13.04 98.82
2017-06-30 0.15 -104.59 11.73 93.47
2017-03-31 0.15 -92.13 12.50 80.30
2016-12-31 0.15 -78.25 9.89 69.23
2016-09-30 0.15 -72.19 10.53 62.20
2016-06-30 0.15 -61.02 9.65 51.98
2016-03-31 0.15 -62.22 13.01 49.71
2015-12-31 0.15 -62.95 15.63 47.71
2015-09-30 0.15 -64.13 16.82 47.59
2015-06-30 0.15 -67.93 18.32 49.71
2015-03-31 0.15 -62.81 17.58 45.29
2014-12-31 0.15 -55.78 15.79 40.09
2014-09-30 0.15 -42.65 13.63 28.71
2014-06-30 0.15 -29.75 11.22 18.32
2014-03-31 0.15 -24.35 7.71 16.50
2013-12-31 0.15 -20.48 6.66 13.66
2013-09-30 0.13 -18.27 6.72 10.99
2013-06-30 0.10 -16.18 6.50 9.24
2013-03-31 0.06 -11.49 6.32 22.43
2012-12-31 0.02 -18.07 4.78 21.03
2012-09-30 -15.58 4.07 20.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if TG Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if TG Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if TG Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess TG Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
TG Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

NKB2 Health

 How is TG Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up TG Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • TG Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • TG Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of TG Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1179.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from TG Therapeutics Company Filings, last reported 3 months ago.

DB:NKB2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 24.04 0.07 68.81
2018-09-30 71.74 0.09 97.74
2018-06-30 101.38 0.21 126.25
2018-03-31 85.23 0.22 109.08
2017-12-31 66.99 0.13 84.72
2017-09-30 79.55 0.18 91.84
2017-06-30 77.98 0.15 86.41
2017-03-31 101.04 0.17 109.46
2016-12-31 35.87 0.07 44.89
2016-09-30 56.75 0.12 60.60
2016-06-30 78.70 0.09 54.26
2016-03-31 89.45 0.15 58.70
2015-12-31 101.57 0.21 77.23
2015-09-30 116.31 0.18 94.16
2015-06-30 112.95 0.30 92.07
2015-03-31 106.23 0.27 105.14
2014-12-31 80.10 0.28 78.78
2014-09-30 67.08 0.18 67.24
2014-06-30 52.10 0.16 45.04
2014-03-31 54.43 0.12 53.50
2013-12-31 40.05 0.74 40.49
2013-09-30 44.64 2.95 50.18
2013-06-30 10.28 3.04 13.42
2013-03-31 14.70 3.10 15.19
2012-12-31 15.55 3.16 16.46
2012-09-30 17.89 5.06 17.37
  • TG Therapeutics's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (1.8% vs 0.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • TG Therapeutics has less than a year of cash runway based on current free cash flow.
  • TG Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 33.9% each year.
X
Financial health checks
We assess TG Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. TG Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

NKB2 Dividends

 What is TG Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from TG Therapeutics dividends.
If you bought €2,000 of TG Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate TG Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate TG Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:NKB2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:NKB2 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as TG Therapeutics has not reported any payouts.
  • Unable to verify if TG Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of TG Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as TG Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess TG Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can TG Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. TG Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

NKB2 Management

 What is the CEO of TG Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike Weiss
COMPENSATION $9,926,616
AGE 52
TENURE AS CEO 7.3 years
CEO Bio

Mr. Michael S. Weiss, also known as Mike, Esq., J.D. has been an Executive Chairman of Mustang Bio Inc. since January 2017 and served as the Interim President and Chief Executive Officer at Mustang Bio Inc. since March 2015 until April 24, 2017 and also served as its President until April 24, 2017. Mr. Weiss serves as the Executive Chairman, Chief Executive Officer and President of TG Therapeutics, Inc. (formerly, Manhattan Pharmaceuticals, Inc.) since December 29, 2011. He co-founded Opus Point Partners, LLC in 2009 and serves as a Co-Portfolio Manager and has been its managing partner and principal since 2009. He is a Partner of Opus Point Partners. Mr. Weiss has been the Chairman of Checkpoint Therapeutics, Inc. since March 2015 and also serves as its Director. He co-founded TG Therapeutics, Inc. in 2011. He has been Executive Vice Chairman of Strategic Development at Fortress Biotech, Inc. (formerly, Coronado Biosciences, Inc.) since February 20, 2014. Mr. Weiss served in several capacities at Fortress Biotech. Mr. Weiss served as Interim Chief Executive Officer and President at Checkpoint Therapeutics, Inc. from March 2015 to December 2016, 2015 and Executive Chairman from March 2015 to December 2016. He served as Chief Executive Officer and Chairman of Keryx Biopharmaceuticals Inc. from December 2002 to April 23, 2009, where he helped it acquire and develop its lead drug Zerenex as well as executed a $100MM+ strategic alliance for Zerenex with Japan Tobacco, Inc. and Torii Pharmaceutical Co., Ltd. Since joined Keryx in December 2002, Mr. Weiss successfully completed the restructuring, an acquisition of a private cancer company, the initiation of a phase II/III clinical program for a lead drug candidate and two equity capital raising transactions of approximately $47 million from leading US-based biotechnology funds. He founded Access Oncology Inc. in 1999 and served as its Chief Executive Officer from 1999 to 2002. He served as the Chief Executive Officer and Chairman of Cancer Education.com Inc., since April 1999. He served as the Secretary of Atlantic Pharmaceuticals Inc. He served as the Secretary of Binary Therapeutics Inc. and BG Development Corp. Mr. Weiss also served at Paligent Inc. He served as Senior Managing Director of Paramount Capital Investments, L.L.C. from November 1993 to March 1999. He served as Senior Managing Director of Aries Funds. He began his professional career as a Lawyer at Cravath, Swaine & Moore LLP and was its Attorney. From 1993 to 1999, he was responsible for negotiating and executing private and public investments in biotechnology companies. He serves as the Chairman of Heavenlydoor.com Inc. (now Paligent Inc.). He had been the Chairman of National Holdings Corporation since September 21, 2016 until June 2018. He served as the Non-Executive Chairman of National Holdings Corporation from January 19, 2011 to April 14, 2012. From March 1999 to December 2002, he served as the Chairman of Access Oncology Inc. He served as Non-Executive Chairman of XTL Biopharmaceuticals Ltd. since August 2005 and also served as its Interim Non-Executive Chairman since March 15, 2005. He served as a Co-Chairman of CB Pharma Acquisition Corp. (now Origo Acquisition Corporation) from August 26, 2014 to June 10, 2016. He served as Co-Vice Chairman of Fortress Biotech, Inc. from December 19, 2013 to January 28, 2014. He has been Executive Vice Chairman of Strategic Development at Fortress Biotech, Inc. since February 2014. He served as a Vice Chairman of Genta Incorporated from May 1997 to September 2005. He had been a Director at National Holdings Corporation since September 9, 2016 until June 11, 2018. He serves as a Member of the Board of Directors of several of the Fortress Biotech’s subsidiaries, including: Aevitas Therapeutics, Inc., Caelum Biosciences, Inc., Cellvation, Inc., Cyprium Therapeutics, Inc., and Tamid Bio, Inc. He has been a Director at Mustang Bio Inc. since 2015. He had been a Non-Executive Director of Avenue Therapeutics, Inc. since February, 2015 till February 8, 2019. He serves as a Director of Palatin Technologies Inc. and Helocyte Inc. He has been a Director of Fortress Biotech, Inc. since December 19, 2013. He has been a Director of TG Therapeutics, Inc. since 2011. Mr. Weiss serves as a Member of the Board of Directors of AVAX Technologies Inc. He served as a Director at TG Therapeutics, Inc. since 2011. He served as a Director of Pacific Pharmaceuticals since 1995. He served as Lead Director at Genta Incorporated since November 2002 and Director since 1997. He served as a Non-Executive Director of XTL Biopharmaceuticals Ltd. since December 1, 2004. He served as a Director of National Holdings Corporation from January 2011 to April 14, 2012. He served as a Director of Keryx Biopharmaceuticals Inc. since 2002. He served as a Director of Healthcare Integrated Services, Inc. since July 1998. He served as a Director of Binary Therapeutics Inc. and BG Development Corp. He is also Executive Vice Chairman of FBIO. He is a Member of Dean’s Advisory Board at School of Business at the University at Albany. He was an Investment Banker and Fund Manager in New York City, focused on biotech and life sciences. Mr. Weiss received a J.D. from Columbia University Law School in 1991 and a B.S. in Finance from The University at Albany in 1984.

CEO Compensation
  • Mike's compensation has increased whilst company is loss making.
  • Mike's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the TG Therapeutics management team in years:

7.3
Average Tenure
  • The average tenure for the TG Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Mike Weiss

TITLE
Executive Chairman
COMPENSATION
$10M
AGE
52
TENURE
7.3 yrs

Sean Power

TITLE
CFO, Corporate Secretary & Treasurer
COMPENSATION
$1M
AGE
36
TENURE
7.3 yrs

Jenna Bosco

TITLE
VP of Investor Relations & Senior VP of Corporate Communications

Adam Waldman

TITLE
Chief Commercial Officer
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the TG Therapeutics board of directors in years:

7
Average Tenure
53
Average Age
  • The tenure for the TG Therapeutics board of directors is about average.
Board of Directors

Laurence Charney

TITLE
Independent Director
COMPENSATION
$237K
AGE
70
TENURE
7 yrs

Mike Weiss

TITLE
Executive Chairman
COMPENSATION
$10M
AGE
52
TENURE
7.3 yrs

Ken Hoberman

TITLE
Independent Director
COMPENSATION
$227K
AGE
53
TENURE
4.3 yrs

Mark Schoenebaum

TITLE
Independent Director
COMPENSATION
$222K
AGE
45
TENURE
7 yrs

William Kennedy

TITLE
Independent Director
COMPENSATION
$222K
AGE
73
TENURE
7 yrs

Yann Echelard

TITLE
Independent Director
COMPENSATION
$222K
AGE
54
TENURE
6.4 yrs

Daniel Hume

TITLE
Independent Director
COMPENSATION
$222K
AGE
51
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
04. Jan 19 Sell Sean Power Individual 02. Jan 19 02. Jan 19 -37,275 €3.64 €-135,565
05. Jul 18 Sell Sean Power Individual 02. Jul 18 03. Jul 18 -47,191 €11.37 €-534,669
18. Jun 18 Sell William Kennedy Individual 14. Jun 18 14. Jun 18 -25,071 €11.55 €-289,490
X
Management checks
We assess TG Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. TG Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

NKB2 News

Simply Wall St News

NKB2 Company Info

Description

TG Therapeutics, Inc., a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin’s Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing. The company has five B-cell targeted drug candidates in clinical development, with the lead two therapies, such as Ublituximab and Umbralisib in pivotal trials for CLL, NHL, and MS. Its Ublituximab is a novel anti-CD20 monoclonal antibody that has been glycoengineered for enhanced potency over first generation antibodies; and Umbralisib is an oral, once daily inhibitor of PI3K delta. The company also develops TG-1501, an anti-PD-L1 monoclonal antibody; TG-1701, an oral Bruton’s Tyrosine Kinase; and TG-1801, an anti-CD47/CD19 bispecific antibody. TG Therapeutics, Inc. has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated; and Jubilant Biosys. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Details
Name: TG Therapeutics, Inc.
NKB2
Exchange: DB
Founded: 1993
$589,751,614
81,874,854
Website: http://www.tgtherapeutics.com
Address: TG Therapeutics, Inc.
2 Gansevoort Street,
9th Floor,
New York,
New York, 10014,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM TGTX Common Stock Nasdaq Capital Market US USD 30. Dec 2011
DB NKB2 Common Stock Deutsche Boerse AG DE EUR 30. Dec 2011
LSE 0VGI Common Stock London Stock Exchange GB USD 30. Dec 2011
Number of employees
Current staff
Staff numbers
105
TG Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/17 22:59
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/04/02
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.